These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37022189)

  • 1. Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use.
    Kim SM; Chong YP; Lee HJ; Shim TS; Jo KW
    Microbiol Spectr; 2023 Jun; 11(3):e0474122. PubMed ID: 37022189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease.
    Chae G; Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0226121. PubMed ID: 35950842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Association Between Sputum Culture Conversion and Mortality in Cavitary Mycobacterium avium Complex Pulmonary Disease.
    Lee JK; Kim S; Chong YP; Lee HJ; Shim TS; Jo KW
    Chest; 2024 Sep; 166(3):442-451. PubMed ID: 38508335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.
    Lee JH; Park YE; Chong YP; Shim TS; Jo KW
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0152221. PubMed ID: 34930036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type
    Jung J; Chong YP; Lee HJ; Shim TS; Jo K-W
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0100323. PubMed ID: 37843254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.
    Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0052822. PubMed ID: 36326247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start?
    Nguyen MH; Daley CL
    Clin Chest Med; 2023 Dec; 44(4):771-783. PubMed ID: 37890915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease.
    Kim OH; Kwon BS; Han M; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW
    Clin Infect Dis; 2019 May; 68(11):1870-1876. PubMed ID: 30239615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.
    Kim HJ; Lee JS; Kwak N; Cho J; Lee CH; Han SK; Yim JJ
    BMC Pulm Med; 2019 Nov; 19(1):212. PubMed ID: 31711459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation.
    Urabe N; Sakamoto S; Tokita N; Yoshida H; Usui Y; Shimizu H; Sekiya M; Miyoshi S; Nakamura Y; Isobe K; Kishi K
    BMC Pulm Med; 2024 Sep; 24(1):442. PubMed ID: 39256717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic Maintenance and Redevelopment of Nontuberculous Mycobacteria Pulmonary Disease after Treatment of Mycobacterium avium Complex Pulmonary Disease.
    Zo S; Kim H; Kwon OJ; Jhun BW
    Microbiol Spectr; 2022 Aug; 10(4):e0108822. PubMed ID: 35950873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
    Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
    Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.
    Ramirez J; Mason C; Ali J; Lopez FA
    J La State Med Soc; 2008; 160(5):248-54; quiz 254, 293. PubMed ID: 19048978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Mycobacterium Avium Complex Pulmonary Disease Treatment Completion and Adherence to ATS/IDSA Guidelines.
    Ku JH; Henkle E; Carlson KF; Marino M; Brode SK; Marras TK; Winthrop KL
    Clin Infect Dis; 2023 Feb; 76(3):e1408-e1415. PubMed ID: 35607719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by
    Griffith DE; Eagle G; Thomson R; Aksamit TR; Hasegawa N; Morimoto K; Addrizzo-Harris DJ; O'Donnell AE; Marras TK; Flume PA; Loebinger MR; Morgan L; Codecasa LR; Hill AT; Ruoss SJ; Yim JJ; Ringshausen FC; Field SK; Philley JV; Wallace RJ; van Ingen J; Coulter C; Nezamis J; Winthrop KL;
    Am J Respir Crit Care Med; 2018 Dec; 198(12):1559-1569. PubMed ID: 30216086
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.
    Zweijpfenning S; Kops S; Magis-Escurra C; Boeree MJ; van Ingen J; Hoefsloot W
    Respir Med; 2017 Oct; 131():220-224. PubMed ID: 28947034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease.
    Ito M; Koga Y; Hachisu Y; Murata K; Sunaga N; Maeno T; Hisada T
    Respir Investig; 2022 Sep; 60(5):613-624. PubMed ID: 35781424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis.
    Park Y; Lee EH; Jung I; Park G; Kang YA
    Respir Res; 2019 Dec; 20(1):286. PubMed ID: 31852452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease.
    Lee BY; Kim S; Hong Y; Lee SD; Kim WS; Kim DS; Shim TS; Jo KW
    Antimicrob Agents Chemother; 2015; 59(6):2972-7. PubMed ID: 25753634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
    Shirley M
    Drugs; 2019 Apr; 79(5):555-562. PubMed ID: 30877642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.